CLASS II Drug recall · Reported 20 Nov 2019 · FDA Enforcement Report

GSMS: Ranitidine Capsules 300 mg recalled by Golden State Medical Supply

Golden State Medical Supply is recalling GSMS: Ranitidine Capsules 300 mg, distributed in Arizona, Iowa, Massachusetts, Missouri. The recall was initiated on 6 Nov 2019 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot Codes: GS023971, Exp. 10/31/2020; GS025527, Exp. 10/31/2020; GS025526, Exp. 10/31/2020; GS026114, Exp. 10/31/2020; GS025813, Exp. 10/31/2020; GS026189, Exp. 10/31/2021; GS027555, Exp. 7/31/2021; GS026190, Exp. 5/31/2021; GS026220, Exp. 05/31/2021; GS026584, Exp. 05/31/2021; GS027139, Exp. 05/31/2021; GS027554, Exp. 05/31/2021.
Quantity recalledN/A

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0308-2020
FDA event ID
84233
Recalling firm
Golden State Medical Supply, Camarillo, CA
Classification
Class II
Status
Terminated
Recall initiated
6 Nov 2019
FDA classified
10 Nov 2019
Reported
20 Nov 2019
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Nitrosamine Impurity

Timeline

6 Nov 2019Recall initiated by company
10 Nov 2019Classified by FDA+4 days
20 Nov 2019Published in enforcement report+10 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations: Presence of NDMA impurity detected in product.

Nitrosamines are impurities that can form during drug manufacturing or storage. Above the FDA acceptable intake limit, long-term exposure may raise cancer risk. The FDA advises patients to keep taking the medicine until they have a replacement.

Product as listed by the FDA

GSMS: Ranitidine Capsules 300 mg, Rx only, 100 count bottles (NDC 51407-098-01) Manufactured by Novitium Pharma LLC, 70 Lake Drive, East Windsor, New Jersey 08520; Packaged by GSMS, Incorporated, Carmillo, CA 93012 USA.

Where it was distributed

AZ, IA, MA, MO

ArizonaIowaMassachusettsMissouri

Questions about this recall

Why was it recalled?

CGMP Deviations: Presence of NDMA impurity detected in product.

Which lots are affected?

Lot Codes: GS023971, Exp. 10/31/2020; GS025527, Exp. 10/31/2020; GS025526, Exp. 10/31/2020; GS026114, Exp. 10/31/2020; GS025813, Exp. 10/31/2020; GS026189, Exp. 10/31/2021; GS027555, Exp. 7/31/2021; GS026190, Exp. 5/31/2021; GS026220, Exp. 05/31/2021; GS026584, Exp. 05/31/2021; GS027139, Exp. 05/31/2021; GS027554, Exp. 05/31/2021.

Where was it sold?

AZ, IA, MA, MO

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

1 other product · FDA event 84233

This product is part of a recall event; the main page for the event is GSMS: Ranitidine Capsules 150 mg recalled by Golden State Medical Supply.

More recalls from Golden State Medical Supply

All 55

Other Gsms: Ranitidine recalls

All 2